NEW YORK (GenomeWeb News) – Leerink Swann downgraded Waters today to Market Perform, saying the company could be challenged by the macroeconomic environment and softer end-markets, as well as increasing competition for its products and services.

Analyst Dan Leonard downgraded the company from a prior rating of Outperform, though he kept the valuation on Waters' stock in the $88 to $89 range.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.

Jul
12
Sponsored by
Canon BioMedical

This webinar will discuss a project that is analyzing the “Human Brainome” – genome, transcriptome, proteome, and phenome interaction data -- to gain insights into Alzheimer’s disease pathogenesis.